Treatment of nonsmall cell lung cancer: Overcoming the resistance to epidermal growth factor receptor inhibitors

Current Opinion in Oncology

Volumn 24, Issue 2, 2012, Pages 123-129

  Carter, Corey A ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

epidermal growth factor receptor; lung cancer; resistance; tyrosine kinase inhibitors

Indexed keywords

AFATINIB; B RAF KINASE; BKM120; CABOZANTINIB; CRIZOTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GEFITINIB; GUANOSINE TRIPHOSPHATE; K RAS PROTEIN; METHIONINE; METMAB; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; NERATINIB; OAM4558 G; PHOSPHATIDYLINOSITOL 3 KINASE; PICTRELISIB; PLACEBO; PROTEIN KINASE; RETASPIMYCIN; SELUMETINIB; SOMATOMEDIN C RECEPTOR; THREONINE; TIVANTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; LUNG NON SMALL CELL CANCER; MESENCHYME CELL; MUTATION; ONCOGENE RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856886733     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834ec6a7     Document Type: Review

References (61)

1. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-354. (Pubitemid 40637826)
2. Lee YJ, Shim HS, Kang YA, et al. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with nonsmall cell lung cancer. J Cancer Res Clin Oncol 2010; 136:1937-1944.
3. Sequist LV. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: Positive nonsmall cell lung cancer patients. J Thorac Oncol 2008; 3 (6 Suppl 2):S143-S145. (Pubitemid 351786746)
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500. (Pubitemid 38720929)
5. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311. (Pubitemid 39209661)
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
7. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735-742.
8. Paz-Ares L, Soulieres D, Melezinek I, et al. Clinical outcomes in nonsmall-cell lung cancer patients with EGFR mutations: Pooled analysis. J Cell Mol Med 2009; 14:51-69.
9. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
10. Suda K, Onozato R, Yatabe Y, Mitsudomi T. EGFR T790M mutation: A double role in lung cancer cell survival? J Thorac Oncol 2009; 4:1-4.
11. Tamborini E, Pricl S, Negri T, et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006; 25:6140-6146. (Pubitemid 44562413)
12. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105:2070-2075. (Pubitemid 351439466)
13. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in nonsmall cell lung cancer. Cancer Res 2006; 66:7854-7858. (Pubitemid 44299146)
14. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359:366-377.
15. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12:6494-6501. (Pubitemid 44799723)
16. Bean J, Riely GJ, Balak M, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14:7519-7525.
17. Chen HJ, Mok TS, Chen ZH, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese nonsmall cell lung cancer. Pathol Oncol Res 2009; 15:651-658.
18. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932-20937.
19. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26. This article is demonstrating molecular profiling of EGFR-sensitizing mutations that have now developed resistance.
20. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043. (Pubitemid 46799492)
21. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-5101. (Pubitemid 32681540)
22. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609-2619. (Pubitemid 351949788)
23. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10:281-289.
24. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable nonsmallcell lung cancer: A comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010; 28:2174-2180.
25. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48:5738-5741.
26. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52 (9 Suppl):2665s-2669s.
27. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2:e17.
28. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-Activated protein kinase pathway. Clin Cancer Res 2008; 14:3651-3656.
29. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909.
30. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000. (Pubitemid 35424092)
31. Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in nonsmall cell lung cancer. Cancer Res 2008; 68:9375-9383.
32. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer cell 2003; 4:257-262. (Pubitemid 37329790)
33. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006; 54:209-215. (Pubitemid 44764916)
34. Kawano O, Sasaki H, Okuda K, et al. PIK3CA gene amplification in Japanese nonsmall cell lung cancer. Lung Cancer 2007; 58:159-160. (Pubitemid 47379973)
35. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007; 57:664-671. (Pubitemid 47353042)
36. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008; 68:6913-6921.
37. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008; 7:665-669. (Pubitemid 351499006)
38. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 2005; 94:29-86. (Pubitemid 41202364)
39. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in nonsmall cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004; 10:6865-6871. (Pubitemid 39383035)
40. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in nonsmall cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61:3986-3997. (Pubitemid 32720961)
41. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2010; 28:3076-3083.
42. Yang C, Shih J, Su W, et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUXLung 2). In: Abstract Presented at the European Society of Medical Oncology (ESMO) Congress; October 2010; Milan; abstract 367PD.
43. Miller VA, Hirsch V, Cadranel J, et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). In: Proceedings of European Society of Medical Oncology (ESMO) Congress; October 2010; Milan; abstract LBA1.
44. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67:11924-11932.
45. Campbell A, Reckamp KL, Camidge DR, et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno nonsmall cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). In: Proceedings of 46th Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 2010; 28 (15Suppl):abstract 7596.
46. Boyer MJ, Blackhall FH, Park K, et al. Efficacy and safety of PF00299805 versus erlotinib: A global, randomized phase 2 trial in patients with advanced nonsmall cell lung cancer after failure of chemotherapy. In: Proceedings of 46th Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 2010; 28 (15 Suppl):abstract LBA7523.
47. Tanaka A, Sueoka-Aragane N, Nakamura T, et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 2011:3874-3880. This article identifies the need for further development of the MET inhibitors.
48. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated nonsmall-cell lung cancer. J Clin Oncol 2011; 29:3307-3315. This article is an example of the need to further molecularly profile pretreatment.
49. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29:2660-2666.
50. Yasenchak C, Nackaerts K, Awada A, et al. Phase 2 results of XL184 in a cohort of patients with advanced non-small cell lung cancer (NSCLC). In: Proceedings of 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 16-19 November 2010; Berlin, Germany.
51. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
52. Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in nonsmall cell lung cancer according to MET alterations. J Thorac Oncol 2011; 6:1624-1631. This article allows confirmation of the need for development of crizotinib in selected MET-Amplified EGFR mutant tumors. This article demonstrates the importance of molecular profiling.
53. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558 g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. In: Proceedings of 47th Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 2011; 29 (Suppl):abstract 7505.
54. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heatshock protein 90 inhibitor, in patients with molecularly defined nonsmall-cell lung cancer. J Clin Oncol 2010; 28:4953-4960. This article demonstrates the lack of activity of HSP-90 inhibitors in EGFR-mutated tumors. This article shows that HSP-90 inhibitors may have a role in EML4-ALK positive tumors.
55. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20:1674-1681.
56. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13:5150-5155. (Pubitemid 47502083)
57. Tolcher AW, Yap TA, Fearen I, et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor, in patients with advanced solid tumor. In: Proceedings of 45th Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol 2009; 27 (15 Suppl):abstract 3503.
58. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-362. (Pubitemid 43128863)
59. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867. (Pubitemid 38410730)
60. Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with nonsmall cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010; 5:1630-1636.
61. Gualberto A, Hixon ML, Karp DD, et al. Pretreatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2010; 104:68-74. Demonstrates that further preclinical screening will be needed to target therapy and improve responses.